Phase III Insulin Add-On Asia Regional Program - ST

Trial Identifier: MB102-137
Sponsor: AstraZeneca
Collaborator:
Bristol-Myers Squibb
NCTID:: NCT02096705
Start Date: March 2014
Primary Completion Date: January 2016
Condition: Endocrine - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100039
China Tianjin, China
China, BEIJING Beijing, BEIJING, China, 100730
China, BEIJING Beijing, BEIJING, China, 100029
China, BEIJING Beijing, BEIJING, China, 100700
China, GUANGDONG Guangzhou, GUANGDONG, China, 510120
China, GUANGDONG Guangzhou, GUANGDONG, China, 510080
China, HEILONGJIANG Haerbin, HEILONGJIANG, China, 150001
China, HUNAN Changsha, HUNAN, China, 410000
China, HUNAN Changsha, HUNAN, China, 410008
China, JIANGSU Nanjing, JIANGSU, China, 210012
China, JIANGSU Suzhou, JIANGSU, China, 215004
China, JIANGSU Wuxi, JIANGSU, China, 214023
China, JILIN Changchun, JILIN, China, 130041
China, SHANGHAI Shanghai, SHANGHAI, China, 200040
China, SHANGHAI Shanghai, SHANGHAI, China, 200080
China, SHANGHAI Shanghai, SHANGHAI, China, 200072
China, SHANGHAI Shanghai, SHANGHAI, China, 200092
China, Shanxi Xi An, Shanxi, China, 710032
China, Shanxi Xi'an, Shanxi, China, 710061
China, SICHUAN Chengdu, SICHUAN, China, 610072
China, SICHUAN Chongqing, SICHUAN, China, 400010
Korea, Republic of Busan, Korea, Republic of, 49241
Korea, Republic of Daegu, Korea, Republic of, 42415
Korea, Republic of Daejeon, Korea, Republic of, 35233
Korea, Republic of Seoul, Korea, Republic of, 06351
Korea, Republic of Seoul, Korea, Republic of, 134-727
Singapore Singapore, Singapore, 169856
Singapore Singapore, Singapore, 529889